Key result
Intravenous administration of purified cTnI in rats and dogs followed a two-compartment pharmacokinetic model with terminal half-lives of 0.8 h and 1.85 h, respectively.
The pharmacokinetic profile of cTnI in rats and dogs demonstrates a fast distribution phase and a relatively slow elimination phase, indicating that blood sampling in cardiotoxicity studies should be targeted based on biomarker kinetics.
May guide cTnI sampling timing in preclinical cardiotoxicity models; leaves open human translation.
Recent improvements in assays have allowed serum cardiac troponin I (cTnI) to be measured at previously undetectable concentrations, which may have implications for cardiotoxicity studies. We characterized the pharmacokinetics of cTnI after a single iv administration of purified cTnI in rats at doses of 0.005, 0.05, and 0.5 μg/kg and in beagle dogs at doses of 0.05, 0.1, and 0.2 μg/kg. Serum cTnI concentration-time profiles were well described by a two-compartment pharmacokinetic model with first-order elimination in both species. The estimated mean (SD) values of total serum clearance, volume of distribution of the central compartment, and terminal half-life were 318 ml/h/kg, 52.9 ml/kg, and 0.8 h in rats and 481 (135) ml/h/kg, 230 (70) ml/kg, and 1.85 (0.5) h in dogs, respectively. In both species, a fast distribution phase was followed by a relatively slow elimination phase. These data indicate that the current practice in cardiotoxicity studies of unguided blood sampling should be revised. A targeted case-by-case approach is required whereby samples are collected not only relative to the kinetics of the test article but also in relation to the kinetics of the biomarker in the test species and the type and severity of anticipated cardiovascular perturbation. This approach is essential for the identification of subtle increases of serum cTnI concentrations in the low dynamic range.
No takes yet. Share an insight, caveat, or question.
Dunn et al. (2011) studied Pharmacokinetics of cardiac troponin I. Purified cardiac troponin I (cTnI) was evaluated on Pharmacokinetic profile (clearance, volume of distribution, terminal half-life). Intravenous administration of purified cTnI in rats and dogs followed a two-compartment pharmacokinetic model with terminal half-lives of 0.8 h and 1.85 h, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: